Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and e...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

justiceforb_85 Jul. 16 at 10:48 PM

$GNLX primary completion date of 12/26 but company states data will be later this year? https://clinicaltrials.gov/study/NCT05281471?term=olvi-vec&rank=1

1 · Reply

Kupper Jun. 29 at 1:57 PM

$GNLX This is getting rediculous. Up 10% and back down again.

0 · Reply

Kupper Jun. 22 at 5:19 PM

$GNLX some day trading this again and playing games.

0 · Reply

Aawilliam2003 Jun. 17 at 6:09 PM

$GNLX well a sell off like this has to be respected? Why? Because insider trading is running rampant these days and this looks like someone dumped hard

0 · Reply

bkfViking123 Jun. 17 at 5:45 PM

$GNLX flash crash

0 · Reply

AmaraNic Jun. 17 at 5:40 PM

$GNLX what is happening

0 · Reply

SuperGreenToday Jun. 17 at 1:50 AM

$GNLX Share Price: $3.04 Contract Selected: Jan 15, 2027 $2.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.73 – $0.89 Potential Upside: 62% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Aawilliam2003 Jun. 9 at 12:41 AM

$GNLX has their phase 3 completed enrollment? If not how can it report out in 2H26?

1 · Reply

AmaraNic Jun. 3 at 5:35 PM

$GNLX half of the days volume hmmm…

0 · Reply

Kupper May. 29 at 2:37 PM

$GNLX this should be at a minimum of $3.50 before it starts to run up when trial results are released.

0 · Reply

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

Jun 16, 2026, 11:00 AM EDT - 5 weeks ago

Genelux Transcript: AGM 2026

2026-05-07T23:07:18.000Z - 2 months ago

Genelux reports Q1 EPS (20c), consensus (19c)

May 7, 2026, 4:15 PM EDT - 2 months ago

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

May 7, 2026, 8:00 AM EDT - 2 months ago

Genelux Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Genelux Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Genelux Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Genelux Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Genelux Proxy statement: Proxy filing

2026-03-20T12:36:29.000Z - 4 months ago

Genelux price target lowered to $20 from $23 at Benchmark

Mar 19, 2026, 4:15 PM EDT - 4 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Genelux Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Genelux Earnings release: Q4 2025

Jan 19, 2026, 8:00 AM EST - 6 months ago

Genelux Transcript: Fireside chat

Jan 12, 2026, 4:00 PM EST - 6 months ago

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

2026-01-08T14:21:22.000Z - 6 months ago

Genelux prices 6.67M shares at $3.00 in underwritten public offering

Jan 8, 2026, 9:13 AM EST - 6 months ago

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

2026-01-07T21:05:55.000Z - 6 months ago

Genelux announces common stock offering, no amount given

Jan 7, 2026, 4:01 PM EST - 6 months ago

Genelux Corporation Announces Proposed Public Offering of Common Stock

2026-01-05T15:55:27.000Z - 7 months ago

Genelux data update indicates disease early control, says H.C. Wainwright

2026-01-05T13:25:52.000Z - 7 months ago

Genelux reports interim data of systemic administration of Olvi-Vec

2026-01-02T13:05:23.000Z - 7 months ago

Genelux appoints Jason Litten as CMO

Jan 2, 2026, 8:00 AM EST - 7 months ago

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

2025-11-05T23:00:37.000Z - 9 months ago

Genelux reports Q3 EPS (21c), consensus (21c)

Nov 5, 2025, 4:20 PM EST - 9 months ago

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Nov 5, 2025, 7:00 AM EST - 9 months ago

Genelux Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Genelux Earnings release: Q3 2025

2025-10-31T15:55:12.000Z - 9 months ago

Genelux initiated with a Buy at Titan Partners

2025-10-21T17:10:40.000Z - 9 months ago

Genelux price target raised to $20 from $10 at Maxim

REPL

2025-10-21T12:00:50.000Z - 9 months ago

Genelux initiated with a Buy at Lake Street

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Genelux Transcript: AGM 2025

2025-08-07T22:00:35.000Z - 1 year ago

Genelux reports Q2 EPS (20c), consensus (22c)

Aug 7, 2025, 4:20 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Genelux Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Genelux Earnings release: Q2 2025

2025-07-21T11:17:30.000Z - 1 year ago

Genelux initiated with a Buy at Lucid Capital

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Genelux Proxy statement: Proxy filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Genelux Proxy statement: Proxy filing

2025-07-07T11:11:07.000Z - 1 year ago

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

RANI

Jul 7, 2025, 7:00 AM EDT - 1 year ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

2025-05-06T21:15:11.000Z - 1 year ago

Genelux reports Q1 EPS (21c), consensus (24c)

May 6, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

May 6, 2025, 8:00 AM EDT - 1 year ago

Genelux Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Genelux Earnings release: Q1 2025

2025-03-28T20:15:24.000Z - 1 year ago

Genelux reports FY24 EPS (95c), consensus (88c)

Mar 28, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Genelux Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Genelux Earnings release: Q4 2024

2025-03-25T18:29:53.000Z - 1 year ago

Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec

2025-03-25T18:29:16.000Z - 1 year ago

Genelux announces alignment with FDA of approval pathway for Olvi-Vec

2025-03-25T18:26:09.000Z - 1 year ago

Genelux prices 3M shares at $3.50 in underwritten public offering

Mar 25, 2025, 8:31 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Feb 3, 2025, 6:45 AM EST - 1 year ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 1 year ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 14, 2024, 7:00 AM EST - 1 year ago

Genelux Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Genelux Earnings release: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 2 years ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Genelux Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Genelux Earnings release: Q2 2024

Jul 30, 2024, 7:00 AM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Genelux Proxy statement: Proxy filing

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Genelux Proxy statement: Proxy filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 2 years ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

May 9, 2024, 8:00 AM EDT - 2 years ago

Genelux Quarterly report: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Genelux Earnings release: Q1 2024

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Genelux Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Genelux Earnings release: Q4 2023

Feb 2, 2024, 7:00 AM EST - 2 years ago

Genelux Registration statement: Registration filing

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Nov 14, 2023, 7:00 AM EST - 2 years ago

Genelux Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Genelux Earnings release: Q3 2023

Sep 14, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 24, 2023, 8:00 AM EDT - 3 years ago

Genelux Proxy statement: Proxy filing

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Genelux Quarterly report: Q2 2023

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Genelux Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 3 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 20, 2023, 4:45 PM EDT - 3 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 20, 2023, 8:00 AM EDT - 3 years ago

Genelux Proxy statement: Proxy filing

Jul 20, 2023, 8:00 AM EDT - 3 years ago

Genelux Proxy statement: Proxy filing

Jul 10, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 28, 2023, 8:00 AM EDT - 3 years ago

Genelux Registration statement: Registration filing

Jun 22, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $18 Million Private Placement

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 3 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 8:00 AM EDT - 3 years ago

Genelux Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 29, 2023, 8:00 AM EDT - 3 years ago

Genelux Annual report: Q4 2022

Mar 23, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 3 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 3 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Jan 10, 2023, 7:00 AM EST - 3 years ago

Genelux Registration statement: Registration filing

Dec 23, 2022, 7:00 AM EST - 3 years ago

Genelux Registration statement: Registration filing

Nov 4, 2022, 8:00 AM EDT - 4 years ago

Genelux Registration statement: Registration filing

Oct 13, 2022, 8:00 AM EDT - 4 years ago

Genelux Registration statement: Registration filing

Sep 19, 2022, 9:08 AM EDT - 4 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

justiceforb_85 Jul. 16 at 10:48 PM

$GNLX primary completion date of 12/26 but company states data will be later this year? https://clinicaltrials.gov/study/NCT05281471?term=olvi-vec&rank=1

1 · Reply

Kupper Jun. 29 at 1:57 PM

$GNLX This is getting rediculous. Up 10% and back down again.

0 · Reply

Kupper Jun. 22 at 5:19 PM

$GNLX some day trading this again and playing games.

0 · Reply

Aawilliam2003 Jun. 17 at 6:09 PM

$GNLX well a sell off like this has to be respected? Why? Because insider trading is running rampant these days and this looks like someone dumped hard

0 · Reply

bkfViking123 Jun. 17 at 5:45 PM

$GNLX flash crash

0 · Reply

AmaraNic Jun. 17 at 5:40 PM

$GNLX what is happening

0 · Reply

SuperGreenToday Jun. 17 at 1:50 AM

0 · Reply

Aawilliam2003 Jun. 9 at 12:41 AM

$GNLX has their phase 3 completed enrollment? If not how can it report out in 2H26?

1 · Reply

AmaraNic Jun. 3 at 5:35 PM

$GNLX half of the days volume hmmm…

0 · Reply

Kupper May. 29 at 2:37 PM

$GNLX this should be at a minimum of $3.50 before it starts to run up when trial results are released.

0 · Reply

Kupper May. 29 at 3:06 AM

$GNLX go ahead and play this short. Pay your premium and take your 10 percent. I have gone ling on this 3 times and made over 100% each time. Wake TF up.

0 · Reply

localmotion2189 May. 22 at 6:57 AM

$GNLX Been holding onto this thing for a while. If (I know that's a big "if") their Phase 2 trials and Phase 3 trials succeed, what do you think their stock price could go up to potentially? I saw the current analyst estimates are around $17-31 (I think), but this factors in the risk of failure, right? So what if the trials actually succeed? What do you guys thinking the likelihood of success is?

1 · Reply

Kupper May. 19 at 4:56 AM

$GNLX no respect for anything good in this world. Shit show made up of shit heads that have no morals or values. Only thing they want is immediate gratification.

1 · Reply

justiceforb_85 May. 10 at 9:22 PM

$GNLX wondering why this has done so poorly? Is there concern for dilution? Drug appears active in ovarian ca but wondering why they are going after lung cancer (where there is significant competition)?

0 · Reply

FrodoBag May. 8 at 10:09 PM

$GNLX this tanked when they pushed back top line results to 2H. Now finally above 3 again on news that those results are still on track for 2H…

0 · Reply

bkfViking123 Apr. 28 at 3:30 PM

back in starter shares of $GNLX while it's under the radar ... 2026 is the year if it hits

1 · Reply

Kupper Apr. 21 at 3:21 PM

$GNLX Up one week down the next week. When will this get the attention it deserves.

0 · Reply

Kupper Apr. 9 at 3:39 PM

$GNLX what is causing the negative price action on this?

3 · Reply

Kupper Mar. 30 at 7:29 PM

$GNLX this is getting rediculously cheap.

1 · Reply

KC1391 Mar. 30 at 1:46 PM

$GNLX is this a buy again now? Buy low sell high

0 · Reply

Market Cap	131.38M
Revenue (ttm)	10,000.00
Net Income (ttm)	-32.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-321,500.02%
Debt to Equity Ratio	0.00

Volume	74,720
Avg Vol	178,366
Day's Range	N/A - N/A
Shares Out	44.84M
Stochastic %K	43%
Beta	0.58
Analysts	Strong Sell
Price Target	$19.00